Categories: News

Broad Institute granted FedRAMP authorization for Terra platform

CAMBRIDGE, Mass., May 24, 2021 /PRNewswire/ — The Broad Institute of MIT and Harvard has been granted an Authority to Operate under the Federal Risk and Authorization Management Program (FedRAMP) for the management and analysis of data on Terra — a cloud-based platform operated by Broad and developed in partnership with Microsoft and Verily, an Alphabet company.

FedRAMP is a US government program that provides federal agencies with a standardized approach to security assessment, authorization, and continuous monitoring for cloud products and services. Being FedRAMP-compliant means a cloud computing system has established and documented a highly secure environment that has withstood comprehensive, rigorous review.

“FedRAMP is a very thorough program of multiple audits and requires demonstration of security at all levels — from technical excellence to documentation,” said David Bernick, chief information security officer at the Broad Institute. “This certification establishes that we have an active and robust security program.”

The certification enables all federal agencies, or projects that are federally funded, to store sensitive data on the Terra platform, use Terra for analyses, and sponsor research activities that also use those data on Terra. This specific authorization has been granted for the National Heart, Lung and Blood Institute, and affirmed by the FedRAMP office in the General Services Administration, to use Terra for handling Moderate-level data.

Terra is now listed on the FedRAMP Marketplace along with other authorized cloud service providers. 

Various NIH entities already use Terra under previous FISMA (Federal Information Security Modernization Act) authorizations, including the All of Us Research Program, the National Human Genome Research Institute’s Genomic Data Analysis, Visualization, and Informatics Lab-Space (AnVIL), the National Heart, Lung, and Blood Institute’s BioDataCatalyst, and the National Cancer Institute.

About Broad Institute of MIT and Harvard
Broad Institute of MIT and Harvard was launched in 2004 to empower this generation of creative scientists to transform medicine. The Broad Institute seeks to describe the molecular components of life and their connections; discover the molecular basis of major human diseases; develop effective new approaches to diagnostics and therapeutics; and disseminate discoveries, tools, methods, and data openly to the entire scientific community.

Founded by MIT, Harvard, Harvard-affiliated hospitals, and the visionary Los Angeles philanthropists Eli and Edythe L. Broad, the Broad Institute includes faculty, professional staff and students from throughout the MIT and Harvard biomedical research communities and beyond, with collaborations spanning over a hundred private and public institutions in more than 40 countries worldwide.

For more information about Terra, please visit https://terra.bio.

View original content to download multimedia:http://www.prnewswire.com/news-releases/broad-institute-granted-fedramp-authorization-for-terra-platform-301298008.html

SOURCE Broad Institute of MIT and Harvard

Staff

Recent Posts

President Trump’s Cannabis Decision Is Coming – And Why MMJ International Holdings Wins Either Way

12 Month Timeline - How Cannabis Rescheduling Actually Takes EffectAnnouncementPresident signals intent or issues executive…

17 hours ago

Accelerating Patient Recruitment and Research Excellence: TrialWire® Supports Endpoints Clinical Trials Day NYC 2025

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- TrialWire®, the industry’s fastest, intelligent patient recruitment…

23 hours ago

Genesis Healthcare Remains Committed to Securing Longterm Stability

The skilled nursing, assisted and senior living provider reiterates dedication to a financial restructuring process…

23 hours ago

Extendicare Announces December 2025 Dividend of C$0.042 per Share

MARKHAM, Ontario, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX:…

23 hours ago

Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026

TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and…

23 hours ago